

**ANIMATE**

Trial  
Number

**A**
**N**
**M**

—

Patient  
Initials

## New Treatment Form (1/2)

This form should be sent with the next due Follow Up Form.

Is this the first round of new treatment  
post nivolumab?

☐

Yes

☐

No

If no, indicate line of new  
treatment following  
nivolumab i.e. 2nd, 3rd etc.

### Systemic treatment for lymphoma

Did the patient receive  
systemic treatment?

☐

Yes

☐

No

Start date of new  
treatment  
(DD/MM/YYYY)

End date of new  
treatment  
(DD/MM/YYYY)

What kind of regimen did the patient receive?

Chemotherapy

☐

Chemotherapy + monoclonal antibody

☐

Monoclonal antibody therapy  
alone

☐

Other  
*Please specify:*
☐

Please specify the drugs used in the regimen given:

Number of cycles given

If excessive toxicity is observed that is considered to be potentially  
due to nivolumab treatment, please submit an SAE form.

### Radiotherapy

Did the patient receive  
radiotherapy?

☐

Yes

☐

No

Start date of new  
treatment  
(DD/MM/YYYY)

End date of new  
treatment  
(DD/MM/YYYY)

Please specify site(s) irradiated:

Radiotherapy dose:

\_\_\_\_\_ Gy

\_\_\_\_\_ Fractions

**ANIMATE**

Trial  
Number

**A**

**N**

**M**

—

Patient  
Initials

## New Treatment Form (2/2)

### Transplant

**For first transplants only, please also complete and submit the Transplant form.**

Did the patient receive a  
transplant?

☐

Yes

☐

No

**Tick box if second or  
subsequent transplant,  
and complete question below**

☐

**For second and subsequent transplants, please indicate type of transplant:**

☐

**Autograft**

☐

**Allograft**

### Response to new treatment

Not due yet

☐

**Please remember to send in an updated report once  
response assessment has been performed**

Date of response  
assessment  
(DD/MM/YYYY)

*Please specify response to treatment by ticking the relevant boxes below:*

PET-CT

☐

Complete Metabolic  
Response (CMR)

☐

Partial Metabolic  
Response (PMR)

☐

No Metabolic Response  
(NMR)

☐

Progressive Metabolic  
Disease (PMD)

*Please see appendix  
3 of the trial protocol  
for guidance*

CT

☐

Complete Response  
(CR)

☐

Partial Response (PR)

☐

Stable Disease (SD)

☐

Progressive Disease  
(PD)

**Completed  
by:**

**Signature:**

*CRFs should only be completed by appropriately qualified  
personnel detailed on the site delegation log*

**Date  
completed:**

D	D	M	M	Y	Y	Y	Y
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

## Additional instructions for completing forms

### New Treatment Form

The New Treatment Form should be completed if a patient receives any further treatment for Hodgkin Lymphoma post-trial treatment.

#### Completing the form

- The form should be submitted as necessary with the next due follow up form.
- If the patient has received **second and subsequent** treatment for their Hodgkin Lymphoma then please complete this form as appropriate.

#### Specific Fields

- **Systemic treatment for Lymphoma** — Please answer *yes* or *no* for 'did the patient receive systemic treatment?'. If answered yes, please complete this section stating the start and end date of treatment, what regimen and how many cycles were given. If excessive toxicity is observed that is considered to be potentially due to nivolumab treatment, please submit an SAE form.
- **Radiotherapy** — Please answer *yes* or *no* for 'did the patient receive radiotherapy?' If answered yes, please complete this section stating the start and end date of treatment, what sites were irradiated and the dose given.
- **Transplant** — Please answer *yes* or *no* for 'did the patient receive a transplant?' If answered yes, please complete and submit the Transplant form (**only required for first transplant**).
- **Response to new treatment**— Please give the response to new treatment and the date of this assessment, or tick the box for *not yet due* if treatment is still ongoing. ~~An update report should then be sent with a subsequent follow up form.~~ If response assessment has not yet been performed, please ensure the New Treatment form is updated with the response once it becomes available and sent to the CTC.

Please see appendix 3 of the trial protocol for further guidance on PET-CT based response assessment.

If you have any questions about how to complete this form please contact the **ANIMATE** Trial Coordinator on: 020 7679 9860